Please check your internet connection and try again.
# Ecospirin (Aspirin) Enteric-Coated
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to prevent dissolution in the stomach, reducing gastric irritation, and allowing absorption in the small intestine.
## Primary Indications
* **Pain and Fever:** Mild to moderate pain and fever.
* **Inflammatory Conditions:** Rheumatoid arthritis, osteoarthritis, other inflammatory arthropathies.
* **Cardiovascular Prevention:** Prevention of myocardial infarction, stroke, and cardiovascular death in patients with established cardiovascular disease or high risk (secondary prevention). In some cases, it may be used for primary prevention, though this is less common and depends on individual risk assessment.
* **Kawasaki Disease:** Treatment and prevention of coronary artery aneurysms.
## Adult Dosing
Dosing varies significantly based on indication.
* **Pain and Fever:** 325 mg to 650 mg every 4-6 hours as needed. Maximum daily dose typically 4000 mg.
* **Inflammatory Conditions:** 2.6 grams to 5.4 grams per day, divided into 3 or 4 doses.
* **Cardiovascular Prevention (Secondary):** 75 mg to 162 mg once daily.
* **Cardiovascular Prevention (Primary):** 81 mg to 162 mg once daily (decision based on individualized risk assessment).
* **Kawasaki Disease:**
* **Acute phase (anti-inflammatory):** 80-100 mg/kg/day divided into 4 doses.
* **Convalescent phase (antiplatelet):** 3-5 mg/kg/day once daily.
## Pediatric Dosing
* **Pain and Fever:** Generally **avoided** in children and teenagers with viral infections (especially influenza and chickenpox) due to the risk of Reye's syndrome. If indicated and no contraindications exist, dosing is typically 10-15 mg/kg/dose every 4-6 hours. Maximum daily dose generally 75 mg/kg/day or 4000 mg/day, whichever is less.
* **Kawasaki Disease:** (See Adult Dosing for specific regimens).
## Dose Adjustments
* **Renal Impairment:** Use with caution. Reduced doses may be necessary in severe impairment.
* **Hepatic Impairment:** Use with caution.
* **Elderly:** Increased risk of adverse effects, particularly gastrointestinal bleeding. Lower doses may be considered.
## Contraindications
* Known hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* History of aspirin-induced asthma, urticaria, or other allergic-type reactions.
* Active peptic ulcer disease or gastrointestinal bleeding.
* Bleeding disorders (e.g., hemophilia).
* Children and teenagers with viral infections (risk of Reye's syndrome).
* Severe hepatic or renal impairment.
* Third trimester of pregnancy.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, heartburn, GI bleeding, ulceration, perforation.
* **Hematologic:** Increased bleeding time, bruising, petechiae, epistaxis. Rarely, thrombocytopenia, anemia.
* **Hypersensitivity:** Bronchospasm, urticaria, angioedema, rash.
* **Ototoxicity:** Tinnitus, hearing loss (typically with higher doses).
* **Reye's Syndrome:** In children and teenagers with viral infections.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** Aspirin can reduce their efficacy.
* **Methotrexate:** Increased methotrexate toxicity.
* **Sulfonylureas:** Aspirin can potentiate hypoglycemic effect.
* **Uricosuric agents (e.g., probenecid):** Aspirin may reduce their efficacy.
* **Alcohol:** Increased risk of GI irritation and bleeding.
## Monitoring
* **GI Symptoms:** Monitor for signs and symptoms of GI bleeding (melena, hematemesis, abdominal pain).
* **Bleeding:** Monitor for easy bruising or prolonged bleeding from cuts.
* **Renal Function:** Monitor BUN and creatinine, especially in patients with risk factors for renal impairment.
* **Hepatic Function:** Monitor LFTs if clinically indicated.
* **Tinnitus:** May indicate dose-related toxicity.
## Clinical Pearls
* The enteric coating allows for gastrointestinal protection but may delay the onset of action compared to non-enteric coated formulations.
* Advise patients to swallow enteric-coated tablets whole and not to crush, chew, or break them.
* Aspirin is a potent antiplatelet agent. Discontinuation should be carefully considered, especially in cardiovascular indications, and timed according to surgical or procedural needs and bleeding risks.
* Use of aspirin for pain and fever in children and adolescents with viral illnesses should be avoided due to the risk of Reye's syndrome.
***
*Please verify the current prescribing information for the most up-to-date and comprehensive details.*
